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Existing clinical case definitions of pertussis are decades old and based largely on clinical presentation in
infants and children, yet an increasing burden is borne by adolescents and adults who may manifest distinct
signs/symptoms. Therefore, a “one-size-fits-all” clinical case definition is no longer appropriate. Seeking to
improve pertussis diagnosis, the Global Pertussis Initiative (GPI) developed an algorithm that delineates the
signs/symptoms of pertussis most common to 3 age groups: 0–3 months, 4 months to 9 years, and ≥10 years.
These case definitions are based on clinical presentation alone, but do include recommendations on labora-
tory diagnostics. Until pertussis can be accurately diagnosed, its burden will remain underestimated, making
the introduction of epidemiologically appropriate preventive strategies difficult. The proposed definitions are
intended to be widely applicable and to encourage the expanded use of laboratory diagnostics. Determination
of their utility and their sensitivity and/or specificity versus existing case definitions is required.
INTRODUCTION
In a previous report, Global Pertussis Initiative
(GPI) participants described the difficulties in defining
pertussis from a clinical perspective [1]. Today, many
different case definitions are used throughout the
world [1–8]. Most case definitions are supplemented
with laboratory and epidemiologic data so that reports
may be categorized as confirmed, probable, or suspect.
Case definitions also vary depending on the situation
in which they are used. For example, in vaccine effi-
cacy trials, specificity is expected to be close to 100%.
Yet, in outbreak situations in states or countries, speci-
ficity is sacrificed to achieve high sensitivity, which is
important for disease prevention and control.
In the prevaccine era, pertussis was considered a
disease of children, and all the present clinical case
definitions reflect this bias. With the current awareness
that pertussis is common in adolescents and adults
and that disease manifestations may be different in
older persons, it is apparent that the “one-size-fits-all”
clinical pertussis case definition is no longer optimal.
In addition, there is an increasing awareness that
pertussis in early infancy has many unique character-
istics that should be recognized in a separate case defi-
nition in order to improve recognition of disease in
this population. In this communication, we provide
background data relating to current case definitions and
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then propose age-stratified case definitions that we believe will
increase diagnostic specificity without decreasing sensitivity.
SELECTED CURRENTLY USED CASE
DEFINITIONS
Selected, currently used, clinical case definitions and additional
laboratory and epidemiologic requirements are presented in
Table 1. Most primary clinical case definitions, such as those by
the World Health Organization (WHO), Centers for Disease
Control and Prevention (CDC), Massachusetts Department of
Health, European Union (EU), Pan American Health Organiz-
ation (PAHO), and Australian Department of Health and Ageing,
have in common a requirement for 2 weeks of cough. To increase
specificity, most definitions require at least 1 additional symptom,
such as paroxysms, inspiratory whoop, or posttussive vomiting.
France requires that cough be present for more than 7 days,
whereas Australia accepts cough of any duration if it is
accompanied by paroxysms, whooping, or vomiting. The EU
also accepts any physician’s diagnosis of pertussis and apnea
as a clinically defining symptom in infants.
Almost all case definitions require laboratory or epidemio-
logic linkage data, and such data may affect whether the case
is categorized as confirmed, probable, or possible. Laboratory
confirmation tests include culture of Bordetella pertussis and
polymerase chain reaction (PCR) assays that are specific for
B. pertussis. Some countries, such as Australia, also accept direct
fluorescent antibody (DFA) testing, whereas the PAHO defi-
nition specifically discourages DFA. Differences are also found
concerning confirmation by serology: the CDC definition does
not include serology, the WHO definition requires paired serol-
ogy, and the EU definition elegantly compromises by requiring
a “B. pertussis–specific antibody response.” France and Massa-
chusetts also accept single serum serology with an elevated
anti–pertussis toxin (anti-PT) titer, and Australia accepts an
immunoglobin A (IgA) response to whole B. pertussis.
THE SENSITIVITY AND SPECIFICITY
OF CLINICAL CASE DEFINITIONS
Recently, Ghanaie and associates [9] studied the sensitivity and
specificity of the WHO pertussis clinical case definition in 328
children aged 6–14 years with a persistent cough for ≥2 weeks.
Pertussis was diagnosed by culture and an IS481 PCR for B.
pertussis or IS1001 PCR for B. parapertussis in nasopharyngeal
swabs. All but 1 of these children had received 3 or more doses of
whole-cell DTP vaccine. The sensitivity was 95.2% and the
specificity was 15.0% with cough ≥2 weeks plus ≥1 of the WHO
clinical criteria. With an increasing number of clinical findings,
sensitivity decreased and specificity increased. Posttussive emesis
was the symptom that had the most pronounced effect in
increasing specificity. As the entry criterion for this study was
cough of >2 weeks’ duration, the mean duration of cough in
the study population was 20 days, and because diagnosis was
made by PCR without serologic study, it is likely that cases
were missed. This would lead to an artificially low specificity.
Between 2001 and 2005, Harnden et al. [10] performed a
prospective cohort study involving 172 children aged 5–16
years who had a cough lasting ≥14 days. Bordetella pertussis in-
fection was diagnosed by the demonstration of a 4-fold change
in immunoglobin G (IgG) antibody to pertussis toxin (PT) in
paired samples or a single IgG titer to PT that was greater than
100 enzyme-linked immunosorbent assay units/mL. In a sub-
sequent analysis, Wang and Harnden [11] used the clinical data
from the 2001–2005 study to examine the sensitivity and speci-
ficity of defined clinical features. In children with a persistent
cough that was characterized as paroxysmal, the sensitivity was
86% and the specificity was 23%; persistent cough with posttus-
sive vomiting had a sensitivity of 70% and a specificity of 61%;
persistent cough with whooping gave a sensitivity of 50% and a
specificity of 74%. To obtain clinical case definition data in ado-
lescents and adults, Wang and Harnden also used the data in
the prospective pertussis surveillance study of Strebel et al. [12]
performed in Minnesota during 1995–1996. In this study,
persons 10–49 years old who presented with an acute paroxys-
mal cough or a persistent cough illness of 7–34 days’ duration
were enrolled. B. pertussis infection was diagnosed by culture,
PCR, or serologic evidence of a titer rise or high single-serum
specimen titer to PT. For paroxysmal cough, the sensitivity was
100% and the specificity was 12%. With posttussive vomiting,
the sensitivity was 56% and the specificity was 68%; for whoop-
ing, the sensitivity was 28% and the specificity was 85%.
In 1998, Patriarca et al. [13] evaluated 15 clinical case defi-
nitions for pertussis during community outbreaks and con-
cluded that a definition of ≥14 days of cough was both
sensitive (77%–91%) and specific (54%–71%) for monitoring
culture-positive cases. However, in nonoutbreak situations, the
use of their case definitions had low sensitivity [14].
CHALLENGES TO CURRENT CRITERIA AND
THE DEVELOPMENT OF NEW CLINICAL
DEFINITIONS OF PERTUSSIS
The present clinical case definitions of pertussis are inconsist-
ent and are not used everywhere. In addition, they are not
universally applicable. Different age groups must be evaluated
by different clinical criteria. Pertussis case definitions may also
differ between endemic and outbreak situations. Furthermore,
resource-rich and resource-limited countries have unique pro-
blems related to the control of pertussis and its diagnosis.
However, in all situations, the true burden of pertussis is
unknown and is significantly underestimated.
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Table 1. Selected Presently Used Pertussis Case Definitions
Organization/
Country, Year Clinical Criteria Laboratory and Epidemiologic Criteria Comment
WHO, 2000 A case diagnosed as pertussis by a physician, or
a person with a cough lasting ≥2 weeks with ≥1 of
the following symptoms:
• paroxysms (ie, fits) of coughing
• inspiratory “whooping”
• posttussive vomiting (ie, vomiting immediately after
coughing) without other apparent cause
Isolation of B. pertussis, or detection of genomic
sequences by PCR, or positive paired serology
Case classification:
clinical case: a case that meets the clinical case
definition, but is not laboratory confirmed.
laboratory-confirmed case: a case that meets the
clinical case definition and is laboratory confirmed.
CSTE/CDC,
2010
A cough illness lasting ≥2 weeks with 1 of the following:
paroxysms of coughing, inspiratory “whoop,” or
posttussive vomiting, without other apparent cause
(as reported by a health professional)
Isolation of B. pertussis from clinical specimen
PCR positive for pertussis
Case classification:
probable: in the absence of a more likely diagnosis,
a cough illness lasting ≥2 weeks, with ≥1 of the
following symptoms:
• paroxysms of coughing or
• inspiratory “whoop”or
• posttussive vomiting
and
• absence of laboratory confirmation, and
• no epidemiologic linkage to a laboratory-
confirmed case of pertussis
confirmed: acute cough illness of any
duration, with isolation of B. pertussis from
a clinical specimen, or cough illness lasting
≥2 weeks, with ≥1 of the following symptoms:
• paroxysms of coughing or
• inspiratory “whoop” or
• posttussive vomiting
and ≥1 of the following:
• PCR positive for pertussis or
• contact with a laboratory-confirmed case
of pertussis
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France, 2009 Patient coughing ≥14 days
with 1 or more of the following:
• whoop
• vomiting
• cyanosis
• apnea
Patient coughing ≥14 days with:
• positive PCR/culture
• >100 IU/mL of anti-PT antibodies >3 year
from vaccination or 100% change in the
antibody titer between 2 serologies at
1-month interval
Epidemiologically confirmed: patient coughing
≥7 days and in contact in the past 20 days with a
biologically confirmed case
Canada, 2009 Suspect case:
one or more of the following,
with no other known cause:
• paroxysmal cough of any duration
• cough with inspiratory “whoop”
• cough ending in vomiting or gagging, or
associated with apnea
Probable case:
cough lasting 2 weeks or longer in the absence of
appropriate laboratory tests and not epidemiologically
linked to a laboratory – confirmed case AND ≥1 of the
following, with no other known cause:
• Paroxysmal cough of any duration
• Cough with inspiratory “whoop”
• Cough ending in vomiting or gagging, or
associated with apnea
Confirmed case:
laboratory confirmation of infection:
• isolation of B. pertussis from an
appropriate clinical specimen or
• detection of B. pertussis DNA from
an appropriate clinical specimen
and
• ≥1 of the following:
‐ cough lasting ≥2 weeks
‐ paroxysmal cough of any duration
‐ cough with inspiratory “whoop”
‐ cough ending with vomiting or gagging, or
associated with apnea
or
• epidemiologic link to a laboratory-
confirmed case and ≥1 of the following
for which there is no other known
cause:
‐ paroxysmal cough of any duration
‐ cough with inspiratory “whoop”
‐ cough ending in vomiting or gagging, or
associated with apnea
Massachusetts,
2009
1989–1992: ≥1 week with paroxysms
or posttussive vomiting
From 1993: cough ≥2 weeks with 1 of the following:
paroxysms, whoop, or posttussive vomiting (CDC
definition)
Bacteriologic cases: positive culture (or + DFA
until 1992), PCR added 2004
Serologic case: positive single-serum anti-
pertussis toxin antibody (persons ≥11 years
only) + clinical case definition
Epidemiologically linked case: contact with a
laboratory confirmed case + clinical case
definition
EU, 2008 Cough ≥2 weeks with ≥1 of the following:
• paroxysms
• inspiratory “whooping”
• posttussive vomiting
or
any person diagnosed as pertussis by a physician
or
apnea episodes in infants
Isolation of B. pertussis
Nucleic acids of B. pertussis
B. pertussis–specific antibody response
Epidemiologic link by human-to-human
transmission
Possible case: any person with clinical criteria
Probable case: person with clinical criteria and
epidemiologic link
Confirmed case: person meeting the clinical and
laboratory criteria
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In resource-rich countries, a major priority relates to the edu-
cation, awareness, and recognition of pertussis in adolescents and
adults and its transmission to infants [15–17]. In order to
improve the awareness and recognition of the disease in these
populations, precise criteria for clinical manifestations of pertussis
are needed (Table 2). Awareness of proper sampling techniques
for obtaining nasopharyngeal specimens (nasopharyngeal swabs,
nasopharyngeal aspiration) for culture and PCR, as well as the
usefulness of single-serum serology in diagnosis should also be
fostered. Finally, awareness of appropriate treatment and chemo-
prophylactic regimens for pertussis should be promulgated.
In resource-limited countries, pertussis burden is especially
underestimated because of a number of factors, including mis-
diagnosis, lack of recognition, and absent requirements for no-
tification. As a result, the burden of pertussis is not recognized
as clinically significant. Adding to the problem is that surveil-
lance systems are often not established or data are collected
only sparsely. Nevertheless, pertussis continues to be a serious
health problem, especially among infants, in terms of both
morbidity and mortality. In addition, because adolescent and
adult pertussis is largely unrecognized, these age groups are
not targeted for prevention and infected individuals are not
treated, thereby facilitating spread of the disease in the com-
munity, including to vulnerable young infants. Finally, labora-
tory access for confirmatory diagnosis is very limited.
Until healthcare professionals in both resource-rich and
research-poor countries diagnose their adolescent and adult per-
tussis patients correctly, the burden of disease will continue to be
significantly underestimated. Without knowing that the disease
predominantly occurs in this population, attempts to increase
vaccine use in adolescents and adults are unlikely to be made.
HOW DO ADVANCES IN DIAGNOSTICS IMPACT
CLINICAL PRACTICE?
In persons with pertussis, the median time from cough onset
to seeking medical care differs by age group. For example, in 1Ta
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Table 2. Considerations Related to Adolescent and Adult
Pertussis
• How is a paroxysmal cough defined? How can it be
distinguished from staccato coughing?
• Is a pertussis-related cough dry? Wet? Hacking? Productive?
• How is an inspiratory “whoop” defined?
• How is a pertussis-related apnea defined? When is it most
likely to occur?
• How can a pertussis-related cough be differentiated from the
cough seen with sinusitis? Asthma? Bronchitis? And that
due to other infectious agents?
• Is the cough worse at night? Are we able to quantify worse?
• Does the cough significantly disturb ability to sleep? How are
we defining sleep disturbance?
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study setting, children aged 7–12 years were seen after 7.8 days
of coughing, whereas adolescents aged 13–18 years were seen
after 12.5 days and adults 17.3 days after symptoms began [18
and Riffelmann M, et al. unpublished data]. The interval from
the onset of cough to when the patient seeks medical care has
a major effect on the laboratory diagnosis of B. pertussis infec-
tion [19–22]. Culture obtained during the first 3 weeks of cough
has 100% specificity, but low sensitivity, ranging from 20% to
80%, when compared with PCR and/or serology. In general,
culture and PCR sensitivity is inversely related to age [23].
Other factors that may influence the sensitivity of culture are
the type and quality of specimen, the type of transport media,
and the duration of transport (optimally within 48 hours).
Real-time (RT)–PCR is more sensitive than culture and is
the diagnostic method of choice in patients with cough illness
of ≤3 weeks’ duration [19]. Selected issues with RT-PCR are
presented in Table 3. In general, by the time most adults seek
medical care, the time windows for both culture and RT-PCR
have passed; therefore, serologic diagnosis should be the
method of choice [18, 19].
Since all adults and most adolescents will have had a pre-
vious B. pertussis infection and/or pertussis immunization,
they will have a rapid anamnestic antibody response to new
B. pertussis infection; consequently, by the time they seek care
for a persistent cough illness, they are likely to have developed
high antibody levels to B. pertussis antigens [21]. PT is unique
to B. pertussis and is highly immunogenic; therefore, it is the
antigen that should be used for single serum diagnosis of B.
pertussis cough illness. Single-serum IgG anti-PT testing has
been used successfully in Massachusetts and in various
countries in Europe for approximately 2 decades [24–26]. High
levels of IgA and/or IgG antibodies to PT were described in
many studies of prolonged cough illness as an accurate indi-
cator of recent pertussis disease [21, 22, 24–29]. In Europe,
single-serum serology for the diagnosis of pertussis has been
intensively studied in the Netherlands [30], and commercial
test kits with a variety of pertussis antigens and varying
degrees of sensitivity and specificity are available [31]. EU re-
ference laboratories have recently suggested recommendations
for the serologic diagnosis of pertussis; these include mainly
quantifying IgG antibodies to PT and reporting results in inter-
national units/mL [32, 33]. In the United States, tests done in
commercial laboratories have varying degrees of sensitivity and
specificity [18]. One widely used test has a specificity of ∼95%
[34]. However, the tests with the greatest sensitivity and speci-
ficity are those that quantifiably measure IgG and IgA anti-
bodies to PT (personal clinical observation of one of the
authors [J. D. C.]). Selected issues with pertussis serology are
presented in Table 3.
SUGGESTED CASE DEFINITIONS FOR
PERTUSSIS
In recognition of the fact that the signs and symptoms of per-
tussis differ by age, we have tailored criteria for pertussis diag-
nosis in 3 different age cohorts (0–3 months, 4 months–9
years, and ≥10 years). These criteria are presented in Figure 1.
In Figure 2, clinical case definitions of pertussis for surveil-
lance purposes are presented.
These case definitions are intended to: (1) be more specific
and/or more sensitive than existing case definitions of pertus-
sis (which were developed more than 40 years ago and were
primarily designed either for surveillance purposes or for
vaccine efficacy studies), (2) be applicable to both resource-
rich and resource-poor settings, (3) encourage the increased
use of laboratory confirmation, and (4) increase the sensitivity
and specificity of pertussis reporting.
If a patient meets 1 or more of the criteria for pertussis
diagnosis, the physician should treat the patient and report
the case to the appropriate health agencies. General comments
on the clinical presentation of pertussis and its laboratory
diagnosis are presented in Tables 4 and 5, respectively.
There are a number of strong indicators of pertussis that
differ by age group. In young infants, the occurrence of coryza
and cough in an afebrile child is usually not alarming. When
these young infants are seen by physicians, they are thought to
have a viral respiratory infection, and the parents are reas-
sured. However, over the next day or two, the parents recog-
nize the worsening of symptoms, but more often than not, the
physicians do not (based on author experience in California
Table 3. Issues Relating to Real-Time Polymerase Chain Reac-
tion and Pertussis Serology
PCR:
• More expensive than culture
• May be difficult to perform (requires trained staff) and to
implement outside the hospital setting (requires dedicated
laboratory space)
• Sensitivity decreases with increasing cough duration
• Commercial kits are not widely available
• Subject to contamination, especially during outbreak situations
Serology:
• Testing is mostly done in immunologically nonnaive populations
• Testing is done with an antigen (pertussis toxin) that is
contained in all acellular vaccines
• Immune response to vaccine antigens cannot be distinguished
from response to infection
• Interpretation of serology depends on vaccination history
• Population-based cutoffs may need verification after change of
vaccination calendar
• Problems in serodiagnosis of B. parapertussis infections
Abbreviation: PCR, polymerase chain reaction.
Clinical Definitions of Pertussis • CID 2012:54 (15 June) • 1761
in 2010 [J. D. C.]). The key indicators of pertussis in these
young infant cases are the afebrile nature of the illness com-
bined with a cough that is increasing in frequency and severity
and a coryza that remains watery. Therefore, the presence of
this triad would be expected to have high sensitivity and good
specificity. The addition of apnea, seizures, cyanosis, emesis,
or pneumonia would result in both high sensitivity and speci-
ficity. In these young infant cases, an elevated white blood cell
count (≥20 000 cells/µL) with absolute lymphocytosis is vir-
tually diagnostic.
In older children (4 months to 9 years), the presence of a
worsening paroxysmal, nonproductive cough of ≥7 days’ dur-
ation in an afebrile child with coryza that has not become
purulent also would indicate high sensitivity and good speci-
ficity for pertussis. As noted with current case definitions, the
addition of whoop, apnea, and posttussive emesis will each
Figure 1. Algorithm for the diagnosis of pertussis. Abbreviations: IgG, immunoglobin G; PCR, polymerase chain reaction; PT, pertussis toxin; RSV,
respiratory syncytial virus; WBC, white blood cell. aIn resource-limited areas where PCR is not available, samples may be sent to a reference laboratory
for culture confirmation. bFalse-negatives possible. cSerology not useful in this age cohort.
Figure 2. Clinical case definition of pertussis for surveillance purposes.
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increase specificity. In those persons ≥10 years of age, the
same triad listed above for those 4 months to 9 years would
also result in high sensitivity with good specificity. In addition,
the notation of sweating episodes between paroxysms will sig-
nificantly increase specificity. In dealing with adult patients, it
is important to ask specific questions about productive cough.
Adults will often say that the cough is productive, but on
further questioning, it is apparent that they actually do not
produce purulent sputum.
The case definitions of pertussis delineated here should first
be tested in clinical trials to determine their utility to the
average clinician and then be compared with existing case
definitions to determine whether they confer increased sensi-
tivity and/or specificity. Although retrospective analyses are
subject to bias, such analyses could be performed first in a
“proof-of-principle” approach. If the new case definitions
appear promising, a prospective study should be conducted to
evaluate the proposed diagnostic criteria in the 3 different age
categories (0–3 months, 4 months to 9 years, ≥10 years).
The protocol we propose would involve the prospective
evaluation of all persons in a defined population with cough ill-
nesses of ≥7 days’ duration stratified into the 3 different age
categories. The study populations should include geographic
regions with different vaccine usage patterns (acellular, whole-
cell, or both). Protocols could be adopted from the Adult Per-
tussis Trial (APERT) and the vaccine efficacy trial in Erlangen,
Germany [12, 35]. In both of these studies, investigators con-
tacted participants every 2 weeks, and all subjects with cough
illness of ≥7 days that was not improving were evaluated. Inten-
sive education programs will be necessary to prevent observer
bias [36]. Studies should be of such duration that they cover the
cyclical epidemiologic patterns of pertussis and include popu-
lations of sufficient size to allow statistical analysis.
The development and utilization of 3 age-related definitions
for pertussis can be expected to increase both the sensitivity
and specificity in its diagnosis, which will result in the recog-
nition of pertussis in all age groups, potentially leading to
better control of pertussis.
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